Newer imidazoline receptor agonists offer a significantly improved tolerability profile compared to traditional centrally acting antihypertensives, potentially supporting their use as alternative agents for hypertension.
No takes yet. Share an insight, caveat, or question.
Supports consideration of imidazoline agonists for hypertension with fewer central effects; leaves open prospective validation of tolerability benefits.
Webster et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: